This trial is looking at whether a gene variant affects microglial activation and TSPO binding in Alzheimer's disease, and if so, what the consequences are.
2 Primary · 0 Secondary · Reporting Duration: Up to 1 year
2 Treatment Groups
No Cognitive Impairment
1 of 2
1 of 2
250 Total Participants · 2 Treatment Groups
Primary Treatment: 11C-ER176 · No Placebo Group · Phase 2
Who is running the clinical trial?
Age 18+ · All Participants · 9 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
What safety measures should be taken when administering 11C-ER176?
"We have rated 11C-ER176 a 2 on our safety scale, as Phase 2 trials typically provide evidence for the former but not the latter." - Anonymous Online Contributor
How many people can participate in this research endeavor?
"Affirmative. According to clinicaltrials.gov, this research study posted on May 11th 2021 is currently recruiting participants. There are 250 spots at a single site for potential patients who meet the criteria." - Anonymous Online Contributor
Is enrollment open to new participants in this research protocol?
"Per clinicaltrials.gov, this medical research is still in need of participants. It was made public on May 11th 2021 and underwent its most recent update on September 15th 2022." - Anonymous Online Contributor